Phaseline

Companies › Bold Therapeutics

Bold Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BOLD-100
GRP78 expression inhibitor
GRP78Phase 1Colorectal CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04421820BOLD-100Phase 1Colorectal CancerOncologyJul 2027

Targets

GRP78 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.